Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 14 h ago

RxSight, Inc.: Point72 Asset Management, L.P. amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Point72 Asset Management amended its Schedule 13G filing on RxSight, Inc., updating its disclosed stake in the ophthalmic medical device maker with the SEC under accession number 0000919574-26-008116. The filing reflects a change to the hedge fund's previously reported position, though the amended document did not immediately specify the revised share count or percentage. RxSight develops adjustable intraocular lenses used in cataract surgery, and its investor base is closely watched for signals on institutional conviction in the small-cap medtech name. The update follows Point72's prior 13G disclosures on the company and comes as passive and active holders recalibrate positions in the sector. Investors will watch for further 13G or 13D amendments to confirm whether the shift reflects a material change in Point72's ownership.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

RxSight, Inc., Point72 Asset Management, L.P.